Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This phase I/Ib trial is to find out the best dose, possible benefits and/or side effects of
ZEN003694 when given in combination with nivolumab with or without ipilimumab in treating
patients with solid tumors. ZEN003694 may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as
nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. Giving ZEN003694 in combination
with nivolumab with or without ipilimumab may shrink or stabilize solid tumors.